ARIAD Pharma Q4 Loss Widens - Quick Facts

(RTTNews) - ARIAD Pharmaceuticals, Inc. (ARIA) reported that its fourth-quarter net loss widened to $74.16 million or $0.40 per share, from a loss of $60.45 million or $0.36 per share, last year. The company said the increase in net loss is primarily due to an increase in operating expenses of $21.6 million, reflecting commercialization of Iclusig, as well as continued development of marketed product and product candidates, offset in part by Iclusig product revenues.

On average, 20 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.47 for the quarter. Analysts' estimates typically exclude special items.

Total revenue increased to $8.35 million, from $74 thousand, a year ago. Analysts expected revenue of $6.31 million for the quarter.